GlassScriptPhysician profile
Shea Wesley
NPI 1932817228
$4,366.03
in general payments reported to CMS, 2019-2025
20 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $163 · 2023: $1,273 · 2024: $1,782 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,031 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,030.68 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $473.36 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $464.23 | 2023-2025 | Absorica Ld, Winlevi, Blu-U |
| Dermavant Sciences, INC. | $449.91 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $403.35 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $355.74 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $316.83 | 2023-2025 | Dupixent |
| Genzyme Corporation | $280.93 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $267.71 | 2023-2025 | |
| Lilly USA, LLC | $245.74 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $236.82 | 2022-2025 | Opzelura, Opzelura |
| Ucb, INC. | $172.16 | 2023-2025 | Bimzelx |
| Pfizer INC. | $148.68 | 2024-2025 | |
| Galderma Laboratories, L.P. | $113.16 | 2024-2025 | Aklief, Nemluvio |
| Leo Pharma INC. | $105.64 | 2023-2025 | Adbry, Anzupgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.36 | 2023-2025 | Spevigo, Cyltezo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $93.34 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $55.44 | 2024-2025 | Cabtreo, Arazlo |
| Solta Medical, A Division of Bausch Health US, LLC | $42.00 | 2024-2025 | Clear & Brilliant |
| Arcutis Biotherapeutics, INC. | $23.75 | 2023 | |
| Amgen INC. | $17.88 | 2024 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shea Wesley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.